

Michael Sands, MD, MPH & TM
July 2005

CURRICULUM VITAE

MICHAEL SANDS, M.D., MPH & TM, FIDSA

Chief, Division of Infectious Diseases
Director, Fellowship Program in Infectious Diseases
University of Florida College of Medicine - Jacksonville

Medical Director
Communicable Diseases Division
Duval County Health Department
Jacksonville, Florida

November 6, 2008

Mailing Address

Infectious Diseases Division
Department of Medicine
University of Florida College of Medicine -Jacksonville
1833 Boulevard, Suite 500
Jacksonville, FL 32206

Education

- 1968: A.B., Rutgers University, New Brunswick, NJ
- 1972: M.D., Georgetown University School of Medicine, Washington, D.C.
- 1975: MPH & TM, Tulane University School of Public Health Tropical Medicine,
New Orleans, LA

Postdoctoral Training

- 1972-1973: Intern in Medicine
St. Mary's Hospital and Medical Center
San Francisco, CA
- 1973-1974: Resident in Internal Medicine
St. Mary's Hospital and Medical Center
San Francisco, CA
- 1974-1975: Postgraduate Student - MPH & TM Program
Tulane University School of Public Health & Tropical Medicine
New Orleans, LA
- 1975-1977: Fellowship in Infectious Diseases, Department of Medicine
Louisiana State University School of Medicine
New Orleans, LA
- 1980-1981: Fellowship in Clinical Microbiology
Department of Pathology, Clinical Microbiology Section
Northwestern Memorial Hospital
Chicago, IL

C.V. Michael Sands, MD, MPH & TM, FIDSA

Licensure

1983: Massachusetts - Inactive

1998-Present: Florida

Board Certifications

1978: American Board of Internal Medicine

1980: American Board of Infectious Diseases

1983: American Board of Pathology - Microbiology

1996: Certificate of Knowledge in Tropical Medicine and Travelers' Health
American Society of Tropical Medicine and Hygiene

Academic Appointments

1975-1977: Assistant Visiting Physician in Medicine
Charity Hospital, New Orleans, LA

1978-1979: Clinical Instructor in Medicine
University of Hawaii School in Medicine
Honolulu, HI

1979-1980: Attending Physician
Infectious Disease Service, Department of Medicine
San Francisco General Hospital
San Francisco, CA

1981-1983: Assistant Professor of Pathology and Medicine
Northwestern University Medical School
Chicago, IL

1983-1996: Assistant Professor of Medicine
Tufts University School of Medicine
Boston, MA

1996-Present: Associate Professor of Medicine
University of Florida Health Sciences Center
Jacksonville, FL

Hospital and Administrative Appointments

1975-1977: Venereologist
City of New Orleans
New Orleans, LA

1977-1978: Infectious Disease Consultant
Kaiser Foundation Hospital
Honolulu, HA
Chief, Hospital Infection Control
Kaiser Foundation Hospital
Honolulu, HA

1978-1980: Internal Medicine Staff, Infectious Disease Consultant
St. Mary's Hospital and Medical Center
San Francisco, CA

C.V. Michael Sands, MD, MPH & TM, FIDSA

- Attending Staff, Internal Medicine
San Francisco General Hospital
San Francisco, CA
- 1979-1980: Chief, Venereal Disease Control
San Francisco Department of Health
San Francisco, CA
- 1981-1983: Chief, Clinical Microbiology Laboratory
VA Lakeside Medical Center
Chicago, IL
- Director, Sexually Transmitted Disease Clinic
Northwestern Medical Faculty Foundation
Chicago, IL
- Infectious Diseases Consulting Staff
Northwestern Memorial Hospital
Chicago, IL
- Clinical Microbiology Attending Staff
Northwestern Memorial Hospital
Chicago, IL
- Consultant, Clinical Mycology, Clinical Microbiology Laboratory
Northwestern Memorial Hospital
Chicago, IL
- 1983-1985: Consultant in Infectious Diseases
Holyoke Hospital
Holyoke, MA
- Consultant in Infectious Diseases
Providence Hospital
Holyoke, MA
- Consultant in Infectious Diseases
Shriners' Hospital
Springfield, MA
- 1983-1996: Director, Clinical Microbiology Laboratory
Department of Pathology, Baystate Medical Center
Springfield, MA
- Consultant in Infectious Diseases
Department of Medicine, Baystate Medical Center
Springfield, MA
- 1985-1996: Director, Travelers Vaccination & Immunization Service
Baystate Medical Center
Springfield, MA

C.V. Michael Sands, MD, MPH & TM, FIDSA

- 1989-1995: Director and Principal Investigator
NIH AIDS Clinical Trials Group (ACTG) Subunit
Baystate Medical Center
Springfield, MA
- 1996-1998: Director, Communicable Diseases
Duval County Health Department
Jacksonville, FL
- Infectious Diseases Attending Staff
Infectious Diseases Division, Department of Medicine
University of Florida Medical Center
Jacksonville, FL
- 1998-Present Chief, Infectious & Communicable Diseases Division
University of Florida & Duval County Health Department
Jacksonville, FL
- Director, Fellowship Program
Infectious Diseases Division
University of Florida/Jacksonville
- Principal Investigator
NIH – CPCRA Smart Study Subunit

Awards and Honors

- 1983; 1992 Ad Hoc Grant Reviewer
National Institute of Child & Human Development
- 1994: CAP Laboratory Inspector
- 2001: Invited Participant – Forum for Collaborative HIV Research – Center for Health Services
Research and Policy, GWV, Washington, DC
- 2008: University of Florida, College of Medicine, Exemplary Teacher Award

Committees

- 1981-1983: Chairman, CME Committee
San Francisco City Clinic
San Francisco, CA
- Secretary, Advisory Committee on Communicable Diseases
Advocates for Public Health
Sacramento, CA
- Consultant, Research Advisory Board
Howard Brown Memorial Clinic
Chicago, IL
- 1982-1983: Infection Control Committee
Outpatient Care Committee
VA Lakeside Medical Center
Chicago, IL
- 1983-1996: Baystate Medical Center

C.V. Michael Sands, MD, MPH & TM, FIDSA

Springfield, MA

Member: Medical Quality Assurance Committee
Internal Medicine Residency Committee
Pathology Council
Research Investigators Committee
Medicine Research Committee
AIDS Multidisciplinary Group Committee
Institutional Review Board (IRB)

Chairman, AIDS Clinical Task Force

- 1996-2006 University of Florida Institutional Review Board
Senior Management Committee – Duval County Health Department
Co-Chair, NE Florida TB Coalition
Chair, Duval County Health Department Research Committee
- 1996-Present: University of Florida/Jacksonville Department of Medicine
Division Chief's Committee
Department of Medicine Fellowship Steering Committee
- 2008 Infectious Diseases Society of America – ID fellows' in-service examination item writing committee

Professional Societies

Infectious Diseases Society of America - Fellow
IDSA HIV Society
Florida Medical Association

Research Grants

- 1984: Sands M and Brown RB
Principal Investigator: Amdicocillin in the Therapy of Serious Gram Negative Infections
Hoffman-LaRoche, Inc.
- 1985: Brown RB and Sands M
Co-Investigator: Role of Endotracheal Tobramycin in the Therapy of Gram Negative Pneumonia
Lilly Research Laboratories
- 1986: Brown RB and Sands M
Co-Investigator: Cefonicid vs Nafcillin in Common Soft Tissue Infections
Smith, Kline and French
- 1986: Brown RB, Sands M and Ryczak M
Co-Investigator: Ceftazadime/Tobramycin vs Ceftazadime/Amikacin in Serious Infections
Lilly Research Laboratories
- 1987: Brown RB, Sands M and Morris A
Co-Investigator: LY146032 vs Conventional Therapy in Gram Positive Infections
Lilly Research Laboratories
- 1988: Sands M and Brown R
Principal Investigator: Fluconazole vs Clotrimazole Toches for Thrush in Patients

C.V. Michael Sands, MD, MPH & TM, FIDSA

- with Malignancy
Pfizer
- 1988: Sands M and Brown R
Principal Investigator: Fluconazole vs Amphotericin B for Esophageal Candidiasis in Patients with Malignancy
Pfizer
- 1988: Sands M and Brown R
Principal Investigator: Fluconazole vs Ketoconazole for Candida Esophagitis in Immunocompromised Patients
Pfizer
- 1988: Brown R, Masamitsu M and Sands M
Co-Investigator: Ceftriazone 500 mg. Daily for the Therapy of Community Acquired Pneumonia
Roche Laboratories
- 1989: Sands M and Brown R
Principal Investigator: Piperacillin/Tazobactrim vs Clindamycin/Gentamicin for Ob/Gyn Infections
Lederle
- 1989: Brown R and Sands M
Co-Investigator: Daptomycin vs Conventional Therapy in the Treatment of Gram Positive Bacteremia and Endocarditis
Lilly Research Labs
- 1989-1994: Sands M
Principal Investigator: AIDS Clinical Trials Groups (ACTG) UMASS Subunit NIH
- 1990: Sands M
Principal Investigator: ACTG Minorities Expansion Grant
NIH
- 1990: Sands M
Principal Investigator: Fluconazole in Empiric Therapy of the Neutropenic Patient
Pfizer
- 1990: Brown R, Sands M, Morris AB and McGee W
Co-Investigator: Ciprofloxacin vs Imipenem/Cilastatin in the Management of Severe Pneumonias
Miles Pharmaceutical
- 1991: O'Grady P, Sands M
Co-Investigator: Unicyn vs Clindamycin Plus Gentamycin for the Therapy of Post-Cesarean Section Endometritis
Pfizer
- 1994: Sands M
Principal Investigator: Delavirdine Phase 2 Antiretroviral Trials
Upjohn
- 1997: Sands M
Principal Investigator: Saquinavir soft gel phase 3 antiretroviral trial NR15520B
Roche Pharmaceutical

C.V. Michael Sands, MD, MPH & TM, FIDSA

- 1997: Sands M
Principal Investigator: A Phase III Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Combination Regimens (DMP 266 + Indinavir, DMP 266 + Zidovudine + Lamivudine, Indinavir + Zidovudine + Lamivudine) in HIV-Infected Patients.
DuPont Merck
- 1998: Sands M
Principal Investigator: A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who are Efavir + Retrovir Experienced and Are Protease-Inhibitor and Non-Nucleoside Reverse Transcriptase-Inhibitor Naïve. (MKC-303)
Triangle Pharmaceutical
- 1998: Sands M
Principal Investigator: A Randomized, Double-Blind Study of MKC-442 Combined with Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients who are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naïve. (MKC-305)
Triangle Pharmaceutical
- 1998: Sands M
Principal Investigator: DMP-266-053 roll over salvage trial for DMP 266-006 virologic failures
- 1998: Sands M
Principal Investigator: A phase II randomized, parallel group, multiple dose study of Lodenosine in combination with stavudine and indinavir in antiretroviral naïve, HIV Infected adult patients (FddA-B001)
U.S. Bioscience
- 1998: Sands M
Principal Investigator: A Randomized Open Label Study to Compare the Effect of Procrit Three Times Weekly Versus Once Weekly in the Treatment of Anemia on the Quality of Life of HIV-Infected Patients. (PR97-29-010)
Ortho Biotech
- 1998: Sands M
Principal Investigator: A phase IV, open-label, randomized, multicenter study to determine the safety and duration of viral suppression of continued therapy with one or two Protease Inhibitors + two NRTI regimen vs substitution therapy with efavirenz + the same NRTI in HIV infected patients (DMP 266-006-049)
DuPont Merck
- 1999: Sands M
Principal Investigator: A phase III trial to determine the efficacy of bivalent AIDSVAX B/B vaccine in adults at risk of sexually transmitted HIV-1 infection in North America (VAX004)
VaxGen
- 1999: Sands M
Principal Investigator: A Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPS) in HIV-Positive Patients. (C97-331-01)
Schering Plough
- 1999: Sands M

C.V. Michael Sands, MD, MPH & TM, FIDSA

- Principal Investigator: Open Label, Non-comparative trial of SCH 56592 in the Treatment of Azole Refractory candidiasis in HIV-infected subjects. (C97-330-17)
Schering Plough
- 1999: Sands M
Principal Investigator: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil as Intensification Therapy in Combination with Highly Active Anti-retroviral Therapy (HAART) in HIV Infected Patients with HIV-1 RNA >50 and ≤400 Copies Per ML. (GS-97-415)
Gilead Sciences
- 1999: Sands M
Co- Investigator: A Phase I/II Study of the Safety and Antiretroviral Activity of Nine Hydroxyurea Regimens in Combination with ddI and d4T. (Right 702)
ABT
- 2000: Sands M
Principal Investigator: A Randomized, Open-Label, Phase III Study of ABT-378/Ritonavir in Combination with Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination with Nevirapine and Two NRTIs in Antiretroviral-Experienced HIV-Infected Subjects (Protocol M98-888)
Abbott Labs
- 2000: Sands M
Principal Investigator: Open label Re-treatment Protocol for HIV-infected Patients with Azole-Refractory Candidiasis (P00298 SCH 56592)
Schering Plough
- 2000: Sands M
Principal Investigator: A 96-Week, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine (40mg BID) + Lamivudine (150mg BID) + Nelfinavir (1250mg BID) versus Abacavir (300mg BID) + Combivir (3TC 150mg/ZDV 300mg BID) versus Combivir (3TC 150mg/ZDV 300mg BID) + Nelfinavir (1250mg BID) in HIV-1 Infected Subjects. (ESS40002)
Glaxo Wellcome
- 2000: Sands M
Principal Investigator: A Randomized, Open label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Anti-Retroviral Naïve Patients. (AG1343-1127)
Agouron Pharmaceuticals
- 2000: Sands M
Principal Investigator: A Phase IV, Open-label, Randomized, Multicenter Study to Determine the Safety and Duration of Viral Suppression of Continued Therapy with One or Two Protease Inhibitors + Two Nucleoside Analogue Reverse Transcriptase Inhibitor Regimen Versus Substitution Therapy with Efavirenz + the Same Two Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-Infected Patients. (DMP 266-049)
DuPont Merck
- 2000: Sands M
Principal Investigator: A Phase II, Randomized, Open-label Comparative Study of Two Different Dosage Regimens of Amprenavir (900mg BID vs. 600mg BID) in Combination with Ritonavir (100mg BID) Plus Abacavir, Another NRTI, and Either Efavirenz or Tenofovir DF in HIV-1 Infected Subjects with Virologic Evidence of Treatment Failure. (ESS40006)
Glaxo Wellcome

C.V. Michael Sands, MD, MPH & TM, FIDSA

- 2000: Sands M
Principal Investigator: Antiretroviral Activity and Tolerability of peg-Intron in HIV-Infected Subjects Failing HAART. (P00737-8)
Schering Plough
- 2000: Sands M
Principal Investigator: Prevalence of Anemia in HIV-Infected Patients (PR99-29-032)
Ortho Biotech
- 2000: Sands M
Principal Investigator: Study of Capravirine (AG-1549) in Combo with Viracept (AG1549-509)
Agouron Pharmaceuticals
- 2000: Sands M
Principal Investigator: A phase IV, randomized, open-label, multicenter, 24-week pilot study to evaluate the efficacy and safety of continued therapy with two nucleoside reverse transcriptase inhibitors NRTS plus 1 protease inhibitor (PI) versus switch to 2 NRTIs plus ziagen (abacavir) 300mg BID in HIV-infected adults with HIV-1 RNA <50 copies/mL (COL30305)
Glaxo Wellcome
- 2000: Sands M
Principal Investigator: Prevalence of anemia in HIV-infected patients. (PR99 29032)
Ortho Biotech
- 2001: Sands M
Principal Investigator: A Phase III, 1:1 Randomized, Double-blind, Controlled, Multicenter Trial Comparing the Efficacy and Safety of Abacavir versus Zidobudine When Combined with Lamivudine and Efavirenz for Treatment of HIV-1 Infection in Antiretroviral Therapy Naïve Adults. (CNA30024)
Glaxo Wellcome
- 2001: Sands M
Principal Investigator: A phase II, pilot, open-label study of once-daily directly observed therapy (DOT) with Epivir 300mg/ziagen 600mg/Agenerase 1200mg/Norvir 200mg in antiretroviral naïve subjects with HIV-1 infection. (COL 40134)
Glaxo Wellcome
- 2001: Sands M
Principal Investigator: A multicenter, open label, randomized study to compare the efficacy and safety of indinavir 800mg BID plus two NRTIs in HIV-1 infected patients who have failed on NNRTI continuing regimen. (CRX497)
Merck and Co, Inc
- 2002: Sands M
Principal Investigator: A phase III, 48-week, randomized, double-blind, multicenter study to evaluate the safety and efficacy of abacavir (ABC) 600mg once-daily (QD) vs abacavir 300mg BID in combination with lamivudine (3TC) (300mg QD) and efavirenz (EFV) (600mg QD) in antiretroviral therapy naïve HIV-1 infected subjects. (CNA30021)
Glaxo Wellcome, Inc
- 2002: Sands M
Principal Investigator: A retrospective, case-control study to investigate genetic polymorphisms in HIV-infected subjects who developed hypersensitivity treatment with abacavir. (CNA30032) GlaxoSmithKline

C.V. Michael Sands, MD, MPH & TM, FIDSA

- 2002: Sands M
Principal Investigator: An open-label, single arm, prospective, multicenter clinical trial to evaluate the efficacy and safety of d4T XR in combination with 3TC and EFV QD in ARV naïve HIV-infected patients. (Daily Antiretroviral Therapy – DART II).
Bristol Myers Squibb Company
- 2002: Sands M
Principal Investigator: Phase 3 study of PEG-Intron in heavily treatment – experienced, HIV-infected patients.
Schering Plough Research Foundation
- 2002: Sands M
Principal Investigator: Single switch in an initial nelfinavir containing failing regimen based on a genotype testing and a virtual phenotype match.
Agouron Pharmaceutical Company
- 2002: Sands M
Principal Investigator: A phase III open label safety study of T20/R029-9800 (HIV-1 fusion inhibitor) in combination with oral ARV in patients who are unable to construct a viable antiviral regimen. (T20-305/NN16391)
Hoffman-LaRoche
- 2002: Sands, M
Principal Investigator: A Randomized, Open-Label Study to Compare the Effect of Procrit (epoetin alfa) Three Times Weekly Versus Once Weekly in the Treatment of Anemia on the Quality of Life of HIV-infected Patients. (PR97-29-010)
Orto-Biotech
- 2002: Sands, M
Multicenter, Open-Label, Early Access Program of Enfuvirtide (FUZEON (t-20)/Ro29-9800, HIV-1 Fusion Inhibitor) in Combination with Free Choice Antiretroviral Regimen to Assess Serious Adverse Events, Serious AIDS Defining Events, and Tolerability in Patients with Advanced HIV-Infection. (Fuzeon EAP)
Trimeris and Hoffman-LaRoche
- 2002: Sands, M
A Phase III Open-Label Safety Study of T-20/Ro29-9800 (HIV-1 fusion inhibitor) in Combination with Oral Antiretrovirals, in Patients who are Unable to Construct a Viable Regimen (T20-305 NV16391)
Trimeris and Hoffman-LaRoche
- 2003: Sands, M
Principle Investigator: An open-label study to evaluate the effect of every other week Procrit (epoetin alfa) dosing on maintaining quality of life and target hemoglobin levels in anemic HIV-infected patients.(PR01-29-024)
Ortho-Biotech
- 2003: Sands, M
Principal Investigator: A Phase III, Randomized, Open-Label, Parallel, Multicenter Study to Evaluate Treatment with Fixed-Dose Combination of Abacavir/Lamivudine (600 mg/300 mg) Once-Dailey Versus Abacavir (300 mg) Twice-Daily and Lamivudine (300 mg) Once-Dailey in Combination with Tenofovir Once-Daily and New PI or NNRTI for 48 Weeks in ART-Experienced HIV-Infected Patients. (CAL 30001) Glaxo Wellcome
- 2003: Sands, M
Principal Investigator: A Phase IV, Open-Label, Randomized, Multicenter Study Switching HIV-1 infected Subjects with a Viral Load <50 Copies/ML on a First PI-Based Regimen to an Efavirenz Substitution Regimen. (Vest-QD)

C.V. Michael Sands, MD, MPH & TM, FIDSA

- Bristol-Myers Squibb
PPD Development
- 2003: Sands, M
Principal Investigator: A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients. (ESS30008)
GlaxoSmithKline
- 2003 : Sands, M
Principal Investigator: A Phase IIIB Atazanavir (BMS-232632) For HIV Infected Individuals: An Early Access Program. (AI424-900)
Bristol-Myers Squibb=
PPD Development
- 2003: Sands, M
Principal Investigator: A Phase IV, Open-Label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir when Administered in Combination with the Abacavir/Lamivudine Fixed-Dose Combination Tablet as a Once Daily Regimen in Antiretroviral-Naïve HIV-1 Infected Subject. (ESS30009)
GlaxoSmithKline
- 2003 - 2007: Sands, M
Principal Investigator: A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART study) (CPCRA 065)
NIH - CPCRA
- 2003: Sands, M
Principal Investigator: A Phase IV, Open-Label, Multicenter Study of Treatment with Trizivir (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-/Daily for 48 Weeks in HIV-Infected Subjects Experiencing Early Virologic Failure (Ziagen Intensification Protocol). (ESS30005)
GlaxoSmithKline
- 2003: Sands, M
Principal Investigator: Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-Dose Ritonavir (TPV/RTV) Versus Genotypically-Defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (RESIST-1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir). (1182.12)
Boehringer Ingelheim
- 2003: Sands, M
Principal Investigator: Multicenter, Open-Label, Early Access Program of Enfuvirtide (FUZEON (t-20)/Ro29-9800, HIV-1 Fusion Inhibitor) in Combination with Free Choice Antiretroviral Regimen to Assess Serious Adverse Events, Serious AIDS Defining Events, and Tolerability in Patients with Advanced HIV-Infection. (MV 16812)
Trimeris and Hoffman-LaRoche
- 2003: Sands, M
Principal Investigator: A Phase III, Open-Label Safety Study of T-20/Ro29-9800 (HIV-1 fusion inhibitor) in Combination with Oral Antiretrovirals, in Patients who are Unable to Construct a Viable Regimen. (T20-305 NV16391)
Trimeris and Hoffman-LaRoche
- 2004: Sands, M

C.V. Michael Sands, MD, MPH & TM, FIDSA

Principal Investigator: A Phase IIIIV, Open-Label, Randomized, Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, each in Combination with Tenofovir and either Didanosine EC or Stavudine XR in HIV-1 Infected Subjects Receiving a NNRTI-Containing HAART Regimen who are Experiencing their First Virologic Failure. AI424103
Bristol-Myers Squibb

- 2004 : Sands, M
Principal Investigator : Evaluation of Single-Dose Ceftributen for Treatment of Uncomplicated Gonococcal Urethritis in Men
Investigator-initiated
- 2005: Sands, M
Principal Investigator: A 12-Week, Prospective, Open-Label, Multicenter, Cohort Study to Assess HIV-Patient Quality of Life and Tolerability After Administration of Enfuvirtide-Containing HAART. (ML18018)
Roche Pharmaceuticals, Inc.
- 2005: Sands, M
Principal Investigator: Observational Cohort Study of Pneumonia in Fuzeon-Exposed and Non-Exposed Patients. (NV17751)
Hoffmann-LaRoche, Inc.
- 2005: Sands, M
Principal Investigator: A Phase IV, Multi-center Cross-sectional Study to Evaluate the I50L Substitution among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir. (AI424128)
Bristol-Myers Squibb
- 2005 : Sands, M
Principal Investigator : A Phase IIIB/IV, Open-Label, Multi-Center Trial to Evaluate the Safety, Tolerability, and Efficacy of HIV-1 Infected Subjects Switching Their Current Protease-Inhibitor Therapies for a Fosamprenavir Therapy Over 48 weeks. (100290)
GlaxoSmithKline
- 2006 : Sands M
Principal investigator : ABC107442: A retrospective case-control study to estimate the sensitivity and specificity of a pharmacogenetic marker (HLA-B*5701) in subjects with and without hypersensitivity to abacavir.

CPCRA 065F: Neurology: A Substudy of A Large, Simple Trial Comparing Two Strategies of Anti-retroviral therapy to Determine the Impact of the Strategies upon Central and Peripheral Nervous System Function.

Principal Investigator – Michael Sands, MD, MPH & TM

CPCRA 065G: Anal Dysplasia: A Substudy of a Large Simple Trial Comparing Two Strategies for Management of Antiretroviral Therapy

Principal Investigator – Michael Sands, MD, MPH & TM

CPCRA 065H: Genomics: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy.

Principal Investigator – Michael Sands, MD, MPH & TM

C.V. Michael Sands, MD, MPH & TM, FIDSA

Referred Journals

1. Sands M and Sanders CV: Serratia marcescens endocarditis. *Annals Internal Medicine* 85:397-98, 1976
2. Sands M and Torres J: Antibacterial activity of emetine. *Proceedings of the Royal Society of Tropical Medicine and Hygiene*. 71:454-55, 1977
3. Sands M, Torres J, Sanders CV: Antibiotic sensitivities of Mycobacterium marinum to the tetracycline derivatives minocycline and doxycycline. *Tubercle* 59:193-95, 1978
4. Sands M: Therapy of pharyngeal gonorrhea. *West J Med* 131:338, 1979
5. Sands M: Treatment of anorectal gonorrhea in men. *JAMA* 243:1143-44, 1980
6. Sands M and Sellers T: Therapy of anorectal gonorrhea in men: Efficacy of oral agents. *West J med* 133:469-71, 1980
7. Sands M: Asymptomatic urethral gonorrhea in gay men. *Sexually Transmitted Diseases* 7:4, 1980
8. Drew WL, Mintz L, Sands M, Ketterer B: CMV infections in homosexual men. *J Infect Dis* 143:188-92, 1981
9. Bolan R, Sands M, Mintz R, Schachter J, Drew WL: Acute ulcerative proctitis from Chlamydia trachomatis. *Am J Med* 72:703-6, 1982
10. Sands M, Sommers HM, Brotman-Rubin M: A simplified schema for speciation of the Viridans streptococci. *Am J Clin Path* 78:78-80, 1982
11. Sands M: Sexually transmitted diseases in homosexual men. *Proc Inst Med (Chicago)* 35:31, 1982
12. Kalish S, Sands M: Pasteurella mulocida infection of a prosthetic vascular graft. *JAMA* 249:514-15, 1983
13. Sands M, Yungbluth M, Sommers MM: Nonvalue of CIE for direct rapid detection of Clostridium difficile toxin in stool filtrates. *Am J Clin Path* 79:375-77, 1983
14. Sands M, Yungbluth M: CIE Assay for C. Difficile Toxin (Authors Reply). *Am J Clin Path* 80:274-75, 1983
15. Sands M, Krohn M, Brown RB: Pentamidine: A Review. *Rev Infec Dis* 7:625-34, 1985
16. Brown RB, Hosmer D, Teres D, Chen HC, Ssands M, Bradley S, Optiz E, Szwedzinski D, and Opalenik D: A comparison of infections in different types of ICU's. *I Crit Care Med* 13:475-476, 1985
17. Schandorf W, Brown RB, Sands M and Hosmer D: Infections in Coronary Care Units. *Am J Card* 56:757-759, 1985
18. Sands M, Phair JP, Huprikar J, Hansen C and Brown RB: A study on antisperm antibody in homosexual men. *J Med* 16:483-91, 1985
19. Sands M, Page D and Brown RB: Splenic abscess following non-operative management of splenic rupture. *J Ped Surg* 21:900-901, 1986

C.V. Michael Sands, MD, MPH & TM, FIDSA

20. Brown RB, Klar J, Lemeshow S, Teres D, Pastides H and Sands M: Enhanced bleeding with Cefoxitin or Moxalactam. A statistical analysis with a defined population of 1493 patients. *Arch Int Med* 146:2159-2164, 1986
21. Ryczak M, Brown R, Sands M: Empiric therapy of infected patients in critical care units. *Hospital Formulary* 21:576-581, 1986
22. Brown R, Sands M, Ryczak M: Community acquired mixed aerobic pneumonia. *Chest* 90:810-814, 1986
23. Brown RB, Sands M, Ficalora R and Jaciow DM: Concurrent community-acquired pneumonia with legionella pneumophila streptococcus pneumoniae. *South Med J* 80:401-406, 1987
24. Sands M, Brown R, Ryczak M, Hamilton W: Streptococcus pneumonia endocarditis: a case report and review of the literature. *Southern Med J* 80:780-782, 1987
25. Ryczak M, Brown R, Sands M: Pneumococcal arthritis in a prosthetic knee. *Clinical Orthopedics Rel Res* 224:224-227, 1987
26. Brown RB, Sands M and Ryczak M: Bleeding as a side effect of antibiotic therapy. *Infect in Med* 4: 386-392, 1987
27. Brown RB, Bradley S, Opitz E, Cipriani D, Pieczarka R and Sands M: Surgical wound infections documented after hospital discharge. *Am J Infect Control* 15:54-58, 1987
28. Brown RB, Sands M and Ryczak M: Management of nosocomial pneumonias. *Hosp Formul* 21:1208-1217, 1986
29. Brown RB, Stechenberg B, Sands M, Hosmer D and Ryczak M: Infections in a pediatric intensive care unit. *Amer Jour Dis Child* 141:267-270, 1987 (Also reprinted in *JAMA, Southeast Asian Edition, Suppl #3, 25-28, 1987*)
30. Sands M, Ryczak M and Brown RB: Recurrent aseptic Meningitis followed by transverse myelitis as a presentation of systemic lupus erthematosus. *J Rheumatol* 15:862-864, 1988
31. Sands M, Brown R: Herpes simplex lymphangitis: two cases and a review of the literature. *Archives of Int Med* 148:2066-2067, 1988
32. Brown RB, Sklar J, Teres D, Lemeshow S, Sands M: A prospective study of clinical bleeding in intensive care unit patients. *Crate Care Med* 16:1171-1176, 1988
33. Brown RB, Phillips D, Barker MJ, Pieczarka R, Sands M and Teres D: An outbreak of nosocomial flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B. *Amer Jour Infect Cont* 17:121-125, 1989
34. Sands M and Brown RB: Interactions of cyclosporin with antimicrobial agents. *Rev Infect Dis* 11:691-697, 1989
35. Sands M, Ashley R, and Brown RB: Trimethoprim/Sulfamethoxazole therapy of Pasteurella multocida infections. *JID* 160:353-354, 1989
36. Morris A, Sands M, Brown RB and Ryczak M: Gallbladder and biliary tract candidiasis: nine cases and a review of the literature. *Rev Infect Dis* 12:483-489, 1990
37. Brown RB and Sands M: Outpatient intravenous antibiotic therapy. *Amer Fam Phys*

C.V. Michael Sands, MD, MPH & TM, FIDSA

40:157-162, 1989

38. Brown RB and Sands M: One-gram intravenous ceftriaxone use in a large teaching hospital. *Curr Ther Res* 46:285-291, 1989
39. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands M and the Endotracheal Tobramycin Study Group: Double-blind study of endotracheal tobramycin in the treatment of gram-negative pneumonia. *Antimicrob Agents Chem* 34:269-272, 1990
40. Brown RB, Sands M and Pyczak M: Therapy of Bacterial Infections. *Infections in Medicine*, 7 (suppl):7-15, 1990
41. Sands M, Brown RB: Interactions of cyclosporine with antimicrobial agents. *Int Med Digest* 6:16-17, 1990
42. Sands M, Poppel D, Brown R: Prototheca wickerhamii peritonitis in a patient on chronic ambulatory peritoneal dialysis. *Rev Infect Dis* 13:376-378, 1991
43. Sands M, Pepe J, Brown RB: Tongue Abscess: a case report and discussion. *Clin Inf Dis* 16:133-135, 1993
44. Brown RB, Garb J, McCue J, Santoro J, Mukherjee D, Sands M: Management of pneumonia by emergency department physicians. *Curr Therap Research* 49:651-658, 1991
45. Morris A, Brown R, Sands M: Use of Rifampin in NonStaphylococcal, Nonmycobacterial Disease. *Antimicrob. Agents Chermther.* 37:1-7, 1993
46. Brown R, Sands M: Community Acquired Mixed Bacterial Pneumonias. *Inf. Dis. in Clin. Practice* 2:32-29, 1993
47. Sands M, Marcus A: Pustulonodular lues, lues maligna, in an HIV infected man. *Clinical Infectious Disease* 20:387-390, 1995
48. Brown R, Sands M: Infectious disease indications for hyperbaric oxygen therapy. *Comprehensive Therapy* 21:663-667, 1995
49. Sands M, Rosenthal E, Chavan A, Snyder B: Mycobaterium marinum tenosynovitis treated with clarithromycin and ethambutol. *Infectious Diseases in Clinical Practice* 5:509-510, 1996
50. Sands M. Guest Editor – STDs in the 1990's. *Jacksonville Medicine* 47, 1996.
51. Sands M A Chlamydia trachomatis primer for the 1990's. *Jacksonville Medicine* 47:189-191, 1996
52. Sands M, McLaughlin G: Communicable Diseases Update: Cyclospora in Florida. *Jacksonville Medicine* 47:446, 1996
53. Sands M, Maloney S: Communicable Diseases Update: Pertussis in Adults. *Jacksonville Medicine* 47:538, 1996
54. Sands M, McCloskey S: Communicable Diseases Update: Prevention of Bicycle Related Injuries. *Jacksonville Medicine* 48:28-29, 1997
55. Sands M, Layland K: Travel Medicine Resources on the Internet. *Jacksonville Medicine* 48:77-78, 1997

C.V. Michael Sands, MD, MPH & TM, FIDSA

56. Polsky B, Hurwitz S, Chuang EL, Wolitz R, Cantrill HL, Heinemann M, Sands ML, et al: Intravitreal Ganciclovir salvage for Cytomegalovirus retinitis in AIDS: AIDS Clinical Trials Group Protocol 085. *Int J Infect Dis* 1:70-71, 1996
57. Sands M, Maloney S: Communicable Diseases Update: Invasive Group A Streptococcal Disease. *Jacksonville Medicine* 48:118-119, 1997
58. Sands M, Htay Z: Communicable Diseases Update: Directly observed therapy (DOT) as a tool for tuberculosis control. *Jacksonville Medicine* 48:267, 1997
59. Nash S, Borgeault R, Sands M: Colonic disease associated with a positive assay for clostridium difficile to HIV and a retrospective study. *J Clin Gastroenterol* 1997; 25:476-479/
60. Sands M, Turner J. HIV reporting begins in Florida. *Jacksonville Medicine* 48:355, 1997.
61. Sands M. Communicable Diseases Update: Influenza 1997. *Jacksonville Medicine* 48:488, 1997.
62. Sands M. Guest Editor. Update on HIV. *Jacksonville Medicine* 50, 1999.
63. Sands M. How close are we to an HIV vaccine? *Jacksonville Medicine* 1999; 50:348-350.
64. Sands M. Guest Editor. Trends in Microbiology. *Jacksonville Medicine* 62:64, 2001.
65. Sands M, Halstead D, Gomez N. The impact of Antimicrobial Resistance on the Choice of Antibiotic Therapy for Uncomplicated Cystitis. *Jacksonville Medicine* 52:76, 2001
66. Mitty JA, Stone VE, Sands M, Macalino G and Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus: a work in progress. *CID* 2002; 34: 984-90
67. Guerrero I, Sands M. Community acquired, bacteremic necrotizing Pseudomonas aeruginosa pneumonia in a previously health women. *Infect Med* 2002; 19:387-389
68. Harro CD, Judson FN, Gorse G, Mayer K, Kostman JR, Brown SJ for the VAX004 Study Group including Sands M. Recruitment and baseline epidemiologic profile of participants in the first phase 3HIV vaccine efficacy trial. *J Acquir Immune Defic Syndr* 2004;37:1385-92
69. The rgp 120 HIV Vaccine study group including Sands M. Placebo-controlled phase 3 trial of recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *JID* 2005;191:654-665
70. Sands M. Clinical Diagnostic Challenge – Orbital Dirofilariasis. *Infect Dis Clin Pract* 2005;13:1-2
71. Crossman A, Mendez J, Vandeveld A, Sands M. Spontaneous bacterial empyema caused by Salmonella enteritidis. *Infect Med* 2006;23:286-288.
72. El-Sadr W and the SMART study group including Sands M. CD4 Guided Antiretroviral treatment interruptions: Results of the SMART study. *NEng J Med* 2006;355:2283-96.

C.V. Michael Sands, MD, MPH & TM, FIDSA

73. Kay R, Vandeveld A, Fiorella P, Crouse R, Blackmore C, Sanderson R, Bailey C and Sands M. An outbreak of healthcare associated multidrug resistant Salmonella Seftenberg in Florida. *Inf Control Hosp Epi* 2007;28:805-11
74. Guzman N, Sands M. The aging face of HIV. *Northeast Florida Medicine* 2007;58:35-36
75. Guzman N, Sands M. The expanding spectrum of Human T-cell lymphotropic virus 1 – associated neurological disease. *Infect Dis Clin Pract* 2007;15:236-238.
76. Sands M, McCarter Y, Sanchez W. Synergy testing of multidrug resistant *Acinetobacter baumannii* against tigecycline and polymyxin using an E-test methodology. *Eur J Clin Microbiol Infect Dis* 2007;26:521-2.
77. The strategies for management of antiretroviral therapy (SMART) study group, including Sands M. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. *JID* 2008;197:1133-44.
78. The strategies for management of antiretroviral therapy (SMART) study group, including Sands M. Inferior clinical outcomes of the CD4 cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4 cell counts and HIV RNA levels during follow-up. *JID* 2008;197:1145-55.
79. Vindas-Cordero J, Sands M, Sanchez W. Austrian’s triad complicated by suppurative pericarditis and cardiac tamponade: A case report and review of the literature. *IJID* 2008
80. Bailey C, Smith V, Sands M. Hepatitis B vaccine: A seven year study of adherence to the immunization guidelines and efficacy in HIV- 1 positive adults. *IJID* 2008; 12:e77 – e83.
81. The SMART/INSIGHT and D:A:D Study Groups, including Sands M. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV infected patients. *AIDS* 2008, 22:F17-F24.
82. Mannepalli S, Sands M, Guzman N, McCarter Y. Pulmonary nocardiosis as the initial presenting infection in HIV/AIDS. *Chest (meeting abstracts)* 2008, 134: C54001